| Metric | Q3 2026 | Q3 2025 |
|---|---|---|
| Revenue | 0.0 | 2.8 |
| Net income | -132.0 | -82.2 |
| EPS (diluted, $ a share) | $-1.32 | $-0.94 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
10-Q filed with the SEC, NASDAQ: KYMR. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
Kymera Therapeutics, Inc.: key numbers
- Share price
- $125.85Close, Nov 16
- Market cap
- $10.7B
- Shares outstanding
- 85.37MLatest SEC cover page
- Sector
- Life Sciences
- Industry
- Biological Products, (No Diagnostic Substances)SIC 2836
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from Kymera Therapeutics, Inc.
All →Kymera Therapeutics Financial Results
Kymera Therapeutics reported financial results for the third quarter ended September 30, 2026, and announced positive Phase 1 data for its IRF5 degrader, KT-579. The company remains well-capitalized with $1.6 billion in cash, providing a runway into 2029, and expects topline Phase 2b data for its STAT6 degrader, KT-621, by year-end 2026.
- Term
- Q3 2026
“Kymera’s recent progress reinforces the opportunity across our portfolio and our ability to help shape a new era of differentiated oral medicines in immunology. With KT-621 and KT-579, we are advancing complementary immunoregulatory mechanisms that target distinct drivers of disease, with significant potential to address unmet needs across the current treatment landscape.”
Nello Mainolfi, PhD, Founder, President and CEO, Kymera Therapeutics
“The positive results from the Phase 1 healthy volunteer trial of KT-579, which we reported today, demonstrate strong translation of its preclinical pharmacology into humans and highlight its potential to modulate multiple core inflammatory pathways through a single oral mechanism.”
Nello Mainolfi, PhD, Founder, President and CEO, Kymera Therapeutics
Kymera Therapeutics CEO Nello Mainolfi Sells $3.41M of Stock
Nello Mainolfi, CEO, sold 30,000 shares of Kymera Therapeutics, Inc. at $111.44 to $116.12 a share (average $113.80) in 6 transactions, worth $3.41M in total on Oct 1, 2026. Shares held after the trade: 666,568 (-0.0%).
- Value
- $3.41M
- Shares
- 30,000
- Average price
- $113.80
- Role
- CEO
- Holding change
- -0.0%
- Trade date
- Oct 1, 2026